Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine plus tesetaxel vs capecitabine plus placebo as second-line therapy in gastric cancer
2010-022164-12Phase 3Withdrawn
- Sponsor
- Genta Incorporated
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and gastric cancer (GC) comparing Capecitabine plus tesetaxel with Capecitabine plus placebo (2 arms). Primary endpoint: Overall survival. Planned start Aug 2011; status: withdrawn.
02
Drugs
tesetaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomagastric cancer (GC)
Beyond the preview
Go deeper on 2010-022164-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022164-12.